Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    17229040 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis
Condition: Cystinosis
Interventions: Drug: Cystagon® (Cysteamine Bitartrate);   Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103)
2 Active, not recruiting Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)
Condition: Cystinosis
Intervention: Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103)
3 Completed
Has Results
Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis
Condition: Cystinosis
Interventions: Drug: Cystagon®;   Drug: RP103

Indicates status has not been verified in more than two years